To include your compound in the COVID-19 Resource Center, submit it here.

Tenofovir alafenamide fumarate: Additional Phase III data

Additional secondary endpoint data from the double-blind, international Phase III Study 110 in 873 hepatitis B e antigen (HBeAg)-positive chronic HBV-infected patients

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE